The "Global Public Health Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
Global Public Health Partnering 2010 to 2020 provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Global Public Health Partnering 2010 to 2020 includes:
Trends in Public Health dealmaking in the biopharma industry since 2010
Analysis of Public Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Public Health deal contract documents
Comprehensive access to over 450 Public Health deal records
The leading Public Health deals by value since 2010
Most active Public Health dealmakers since 2010
The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Public Health dealmaking
2.2. Public Health partnering over the years
2.3. Public Health partnering by deal type
2.4. Public Health partnering by industry sector
2.5. Public Health partnering by stage of development
2.6. Public Health partnering by technology type
2.7. Public Health partnering by therapeutic indication
Chapter 3 -Financial deal terms for Public Health partnering
3.2. Disclosed financials terms for Public Health partnering
3.3. Public Health partnering headline values
3.4. Public Health deal upfront payments
3.5. Public Health deal milestone payments
3.6. Public Health royalty rates
Chapter 4 - Leading Public Health deals and dealmakers
4.2. Most active in Public Health partnering
4.3. List of most active dealmakers in Public Health
4.4. Top Public Health deals by value
Chapter 5 - Public Health contract document directory
5.2. Public Health partnering deals where contract document available
Chapter 6 - Public Health dealmaking by therapeutic target
6.2. Deals by Public Health therapeutic target
Appendix 1 - Directory of Public Health deals by company A-Z 2010 to 2020
Appendix 2 - Directory of Public Health deals by deal type 2010 to 2020
Appendix 3 - Directory of Public Health deals by stage of development 2010 to 2020
Appendix 4 - Directory of Public Health deals by technology type 2010 to 2020
For more information about this report visit https://www.researchandmarkets.com/r/v97kb7
View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005254/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900